WSGR logoWSGR logo
Nguyen T. Pham
Of Counsel
Technology Transactions
Palo Alto
Los Angeles

D650-849-3266

Download vCard
Open PDF
  • Leading Life Sciences Representation

    Nguyen focuses on the life sciences industry, representing innovative and leading companies and notable venture capital investors.

  • Comprehensive Transactional Experience

    Nguyen represents her clients in their strategic and IP-based transactional matters, including transactions with major biopharmaceutical and medical device companies, leading investors, and internationally recognized public and private research universities and institutions.

Nguyen Pham is Of Counsel in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Nguyen advises life sciences and technology companies on legal and business issues associated with the development, manufacture, and commercialization of their products, services, and intellectual property assets. Her practice focuses on representing public and private companies, including start-ups, in complex partnering and licensing arrangements, mergers and acquisitions, spin-outs, collaboration agreements, license agreements with academic and nonprofit institutions, research and development agreements, clinical trial agreements, and manufacturing, supply, and distribution agreements.

Experience

Nguyen Pham is Of Counsel in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Nguyen advises life sciences and technology companies on legal and business issues associated with the development, manufacture, and commercialization of their products, services, and intellectual property assets. Her practice focuses on representing public and private companies, including start-ups, in complex partnering and licensing arrangements, mergers and acquisitions, spin-outs, collaboration agreements, license agreements with academic and nonprofit institutions, research and development agreements, clinical trial agreements, and manufacturing, supply, and distribution agreements.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises on Juvena Therapeutics on IP Matters Related to $33.5 Million Series B
On January 12, 2026, Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, announced its $33.5 million Series B. The financing round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray. Wilson Sonsini Goodrich & Rosati advised Juvena on IP matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.

The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.